000005125312/312024Q2falsehttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiff:Positioniff:positioniff:segmentiso4217:EURiff:swap00000512532024-01-012024-06-300000051253dei:OtherAddressMember2024-01-012024-06-300000051253us-gaap:CommonStockMember2024-01-012024-06-300000051253iff:A1.800SeniorNotesDue2026Member2024-01-012024-06-3000000512532024-07-3100000512532024-04-012024-06-3000000512532023-04-012023-06-3000000512532023-01-012023-06-300000051253iff:PharmaSolutionsMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-04-012024-06-3000000512532024-06-3000000512532023-12-310000051253us-gaap:CommonStockMember2023-03-310000051253us-gaap:AdditionalPaidInCapitalMember2023-03-310000051253us-gaap:RetainedEarningsMember2023-03-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000051253us-gaap:TreasuryStockCommonMember2023-03-310000051253us-gaap:NoncontrollingInterestMember2023-03-3100000512532023-03-310000051253us-gaap:RetainedEarningsMember2023-04-012023-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000051253us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000051253us-gaap:TreasuryStockCommonMember2023-04-012023-06-300000051253us-gaap:CommonStockMember2023-06-300000051253us-gaap:AdditionalPaidInCapitalMember2023-06-300000051253us-gaap:RetainedEarningsMember2023-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000051253us-gaap:TreasuryStockCommonMember2023-06-300000051253us-gaap:NoncontrollingInterestMember2023-06-3000000512532023-06-300000051253us-gaap:CommonStockMember2024-03-310000051253us-gaap:AdditionalPaidInCapitalMember2024-03-310000051253us-gaap:RetainedEarningsMember2024-03-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000051253us-gaap:TreasuryStockCommonMember2024-03-310000051253us-gaap:NoncontrollingInterestMember2024-03-3100000512532024-03-310000051253us-gaap:RetainedEarningsMember2024-04-012024-06-300000051253us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000051253us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000051253us-gaap:TreasuryStockCommonMember2024-04-012024-06-300000051253us-gaap:CommonStockMember2024-06-300000051253us-gaap:AdditionalPaidInCapitalMember2024-06-300000051253us-gaap:RetainedEarningsMember2024-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000051253us-gaap:TreasuryStockCommonMember2024-06-300000051253us-gaap:NoncontrollingInterestMember2024-06-300000051253us-gaap:CommonStockMember2022-12-310000051253us-gaap:AdditionalPaidInCapitalMember2022-12-310000051253us-gaap:RetainedEarningsMember2022-12-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000051253us-gaap:TreasuryStockCommonMember2022-12-310000051253us-gaap:NoncontrollingInterestMember2022-12-3100000512532022-12-310000051253us-gaap:RetainedEarningsMember2023-01-012023-06-300000051253us-gaap:NoncontrollingInterestMember2023-01-012023-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000051253us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300000051253us-gaap:TreasuryStockCommonMember2023-01-012023-06-300000051253us-gaap:CommonStockMember2023-12-310000051253us-gaap:AdditionalPaidInCapitalMember2023-12-310000051253us-gaap:RetainedEarningsMember2023-12-310000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000051253us-gaap:TreasuryStockCommonMember2023-12-310000051253us-gaap:NoncontrollingInterestMember2023-12-310000051253us-gaap:RetainedEarningsMember2024-01-012024-06-300000051253us-gaap:NoncontrollingInterestMember2024-01-012024-06-300000051253us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300000051253us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300000051253us-gaap:TreasuryStockCommonMember2024-01-012024-06-300000051253srt:ScenarioPreviouslyReportedMember2023-04-012023-06-300000051253srt:ScenarioPreviouslyReportedMember2023-01-012023-06-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2024-06-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2024-01-012024-06-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2023-01-012023-06-300000051253iff:TradeAccountsReceivableWithTheCompanysOwnFactoringAgreementsMember2023-12-310000051253iff:EmployeeStockOptionAndRestrictedStockMember2024-04-012024-06-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2023-04-012023-06-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2024-01-012024-06-300000051253iff:EmployeeStockOptionAndRestrictedStockMember2023-01-012023-06-300000051253iff:ShareEquivalentsMember2024-04-012024-06-300000051253iff:ShareEquivalentsMember2023-04-012023-06-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-04-022024-04-020000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-04-020000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-01-012024-06-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-04-012024-06-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-07-012024-06-300000051253us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-07-012023-12-310000051253iff:SavorySolutionsBusinessMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-05-310000051253iff:SavorySolutionsBusinessMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-01-012023-06-300000051253iff:SavorySolutionsBusinessMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-04-012023-06-300000051253iff:SavorySolutionsBusinessMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2023-10-012023-12-310000051253iff:SavorySolutionsBusinessMemberus-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2023-01-012023-06-300000051253iff:PharmaSolutionsMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-06-300000051253iff:PharmaSolutionsMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-01-012024-06-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2024-06-300000051253us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberiff:CosmeticIngredientsMember2023-12-310000051253iff:NutritionBiosciencesIncMember2024-01-012024-06-300000051253iff:NutritionBiosciencesIncMember2024-06-300000051253iff:A2023RestructuringProgramMember2024-01-012024-06-300000051253iff:A2023RestructuringProgramMember2024-06-300000051253iff:NutritionBiosciencesIncMemberus-gaap:OtherRestructuringMember2023-12-310000051253iff:NutritionBiosciencesIncMemberus-gaap:OtherRestructuringMember2024-01-012024-06-300000051253iff:NutritionBiosciencesIncMemberus-gaap:OtherRestructuringMember2024-06-300000051253iff:A2023RestructuringProgramMemberus-gaap:EmployeeSeveranceMember2023-12-310000051253iff:A2023RestructuringProgramMemberus-gaap:EmployeeSeveranceMember2024-01-012024-06-300000051253iff:A2023RestructuringProgramMemberus-gaap:EmployeeSeveranceMember2024-06-300000051253iff:NourishMember2024-04-012024-06-300000051253iff:NourishMember2023-04-012023-06-300000051253iff:NourishMember2024-01-012024-06-300000051253iff:NourishMember2023-01-012023-06-300000051253iff:HealthBiosciencesMember2024-04-012024-06-300000051253iff:HealthBiosciencesMember2023-04-012023-06-300000051253iff:HealthBiosciencesMember2024-01-012024-06-300000051253iff:HealthBiosciencesMember2023-01-012023-06-300000051253iff:ScentMember2024-04-012024-06-300000051253iff:ScentMember2023-04-012023-06-300000051253iff:ScentMember2024-01-012024-06-300000051253iff:ScentMember2023-01-012023-06-300000051253iff:PharmaSolutionsMember2024-04-012024-06-300000051253iff:PharmaSolutionsMember2023-04-012023-06-300000051253iff:PharmaSolutionsMember2024-01-012024-06-300000051253iff:PharmaSolutionsMember2023-01-012023-06-300000051253iff:EquityBasedAwardsMember2024-04-012024-06-300000051253iff:EquityBasedAwardsMember2023-04-012023-06-300000051253iff:EquityBasedAwardsMember2024-01-012024-06-300000051253iff:EquityBasedAwardsMember2023-01-012023-06-300000051253iff:LiabilityBasedAwardsMember2024-04-012024-06-300000051253iff:LiabilityBasedAwardsMember2023-04-012023-06-300000051253iff:LiabilityBasedAwardsMember2024-01-012024-06-300000051253iff:LiabilityBasedAwardsMember2023-01-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2024-04-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2023-04-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2024-01-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:NourishMember2023-01-012023-06-300000051253iff:HealthBiosciencesMemberus-gaap:OperatingSegmentsMember2024-04-012024-06-300000051253iff:HealthBiosciencesMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000051253iff:HealthBiosciencesMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-300000051253iff:HealthBiosciencesMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2024-04-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2023-04-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2024-01-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:ScentMember2023-01-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2024-04-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2023-04-012023-06-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2024-01-012024-06-300000051253us-gaap:OperatingSegmentsMemberiff:PharmaSolutionsMember2023-01-012023-06-300000051253us-gaap:EMEAMember2024-04-012024-06-300000051253us-gaap:EMEAMember2023-04-012023-06-300000051253us-gaap:EMEAMember2024-01-012024-06-300000051253us-gaap:EMEAMember2023-01-012023-06-300000051253srt:AsiaMember2024-04-012024-06-300000051253srt:AsiaMember2023-04-012023-06-300000051253srt:AsiaMember2024-01-012024-06-300000051253srt:AsiaMember2023-01-012023-06-300000051253srt:NorthAmericaMember2024-04-012024-06-300000051253srt:NorthAmericaMember2023-04-012023-06-300000051253srt:NorthAmericaMember2024-01-012024-06-300000051253srt:NorthAmericaMember2023-01-012023-06-300000051253srt:LatinAmericaMember2024-04-012024-06-300000051253srt:LatinAmericaMember2023-04-012023-06-300000051253srt:LatinAmericaMember2024-01-012024-06-300000051253srt:LatinAmericaMember2023-01-012023-06-300000051253country:USus-gaap:GeographicConcentrationRiskMember2024-04-012024-06-300000051253country:USus-gaap:GeographicConcentrationRiskMember2023-04-012023-06-300000051253country:USus-gaap:GeographicConcentrationRiskMember2024-01-012024-06-300000051253country:USus-gaap:GeographicConcentrationRiskMember2023-01-012023-06-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2024-04-012024-06-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2023-04-012023-06-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2024-01-012024-06-300000051253iff:AllForeignCountriesMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-06-300000051253us-gaap:SalesMemberiff:AllForeignCountriesMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300000051253us-gaap:SalesMemberiff:AllForeignCountriesMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300000051253us-gaap:PensionPlansDefinedBenefitMembercountry:US2024-04-012024-06-300000051253us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-04-012023-06-300000051253us-gaap:PensionPlansDefinedBenefitMembercountry:US2024-01-012024-06-300000051253us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-01-012023-06-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-04-012024-06-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-04-012023-06-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-06-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-06-300000051253us-gaap:PensionPlansDefinedBenefitMembercountry:US2024-06-300000051253us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-06-300000051253country:USus-gaap:QualifiedPlanMember2024-01-012024-06-300000051253us-gaap:NonqualifiedPlanMembercountry:US2024-01-012024-06-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-04-012024-06-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-04-012023-06-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-06-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-06-300000051253us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-06-300000051253us-gaap:OtherLiabilitiesMember2024-06-300000051253us-gaap:ForeignCountryMember2024-06-300000051253us-gaap:DomesticCountryMember2024-06-300000051253us-gaap:LandMember2024-06-300000051253us-gaap:LandMember2023-12-310000051253us-gaap:BuildingAndBuildingImprovementsMember2024-06-300000051253us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000051253us-gaap:MachineryAndEquipmentMember2024-06-300000051253us-gaap:MachineryAndEquipmentMember2023-12-310000051253us-gaap:TechnologyEquipmentMember2024-06-300000051253us-gaap:TechnologyEquipmentMember2023-12-310000051253us-gaap:ConstructionInProgressMember2024-06-300000051253us-gaap:ConstructionInProgressMember2023-12-310000051253iff:NourishMember2023-12-310000051253iff:HealthBiosciencesMember2023-12-310000051253iff:ScentMember2023-12-310000051253iff:PharmaSolutionsMember2023-12-310000051253iff:NourishMember2024-06-300000051253iff:HealthBiosciencesMember2024-06-300000051253iff:ScentMember2024-06-300000051253iff:PharmaSolutionsMember2024-06-300000051253us-gaap:CustomerRelationshipsMember2024-06-300000051253us-gaap:CustomerRelationshipsMember2023-12-310000051253us-gaap:TechnologyBasedIntangibleAssetsMember2024-06-300000051253us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000051253us-gaap:TrademarksAndTradeNamesMember2024-06-300000051253us-gaap:TrademarksAndTradeNamesMember2023-12-310000051253us-gaap:OtherIntangibleAssetsMember2024-06-300000051253us-gaap:OtherIntangibleAssetsMember2023-12-310000051253iff:HealthWrightProductsIncHealthWrightMember2024-04-012024-06-300000051253iff:HealthWrightProductsIncHealthWrightMember2024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyEightMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentyEightMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortyEightMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFortyEightMemberus-gaap:LoansPayableMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:LoansPayableMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:LoansPayableMember2023-12-310000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2024-06-300000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2023-12-310000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2024-06-300000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2023-12-310000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2024-06-300000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2023-12-310000051253iff:BankBorrowingsAndOverdraftsMember2024-06-300000051253iff:BankBorrowingsAndOverdraftsMember2023-12-310000051253srt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberiff:EurocurrencyRateMemberiff:CitibankN.AMember2021-07-282021-07-280000051253us-gaap:RevolvingCreditFacilityMemberiff:EurocurrencyRateMemberiff:CitibankN.AMembersrt:MaximumMember2021-07-282021-07-280000051253us-gaap:BaseRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberiff:CitibankN.AMember2021-07-282021-07-280000051253us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMemberiff:CitibankN.AMembersrt:MaximumMember2021-07-282021-07-280000051253us-gaap:RevolvingCreditFacilityMemberiff:CitibankN.AMember2024-01-012024-06-300000051253us-gaap:RevolvingCreditFacilityMemberiff:CitibankN.AMember2023-01-012023-06-300000051253iff:A2024TermLoanMemberus-gaap:LoansPayableMember2024-02-012024-02-010000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:LoansPayableMember2024-03-142024-03-140000051253iff:A2026TermLoanMemberus-gaap:LoansPayableMember2024-01-012024-06-300000051253iff:SeniorNotesDueTwoThousandTwentyThreeMemberus-gaap:LoansPayableMember2023-01-012023-06-300000051253us-gaap:RevolvingCreditFacilityMemberus-gaap:LoansPayableMember2023-01-012023-06-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentyFiveMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesEuroNotesDueTwoThousandTwentySixMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253iff:SeniorNotesDueTwoThousandTwentySevenMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2024-06-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandTwentyEightMember2023-12-310000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2024-06-300000051253iff:SeniorNotesDueTwoThousandThirtyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandThirtyMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFortyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFortySevenMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortySevenMember2023-12-310000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2024-06-300000051253us-gaap:CarryingReportedAmountFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:SeniorNotesDueTwoThousandFortyEightMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-06-300000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253iff:SeniorNotesDueTwoThousandFiftyMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310000051253iff:A2024TermLoanMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2024TermLoanMember2024-06-300000051253iff:A2024TermLoanMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2024TermLoanMember2023-12-310000051253iff:A2026TermLoanMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-06-300000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2026TermLoanMember2024-06-300000051253iff:A2026TermLoanMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310000051253us-gaap:EstimateOfFairValueFairValueDisclosureMemberiff:A2026TermLoanMember2023-12-310000051253iff:EuroNotesMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000051253us-gaap:DesignatedAsHedgingInstrumentMemberiff:A2022CrossCurrencySwapsMember2024-06-300000051253iff:A2022CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-06-300000051253us-gaap:ForwardContractsMember2024-06-300000051253us-gaap:ForwardContractsMember2023-12-310000051253us-gaap:CommodityContractMember2024-06-300000051253us-gaap:CommodityContractMember2023-12-310000051253us-gaap:CurrencySwapMember2024-06-300000051253us-gaap:CurrencySwapMember2023-12-310000051253us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2024-06-300000051253us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2024-06-300000051253us-gaap:ForeignExchangeContractMember2024-06-300000051253us-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000051253us-gaap:NondesignatedMember2024-06-300000051253us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-300000051253us-gaap:NondesignatedMemberus-gaap:CurrencySwapMember2024-06-300000051253us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-12-310000051253us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-12-310000051253us-gaap:ForeignExchangeContractMember2023-12-310000051253us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000051253us-gaap:NondesignatedMember2023-12-310000051253us-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000051253us-gaap:NondesignatedMemberus-gaap:CurrencySwapMember2023-12-310000051253us-gaap:ForeignExchangeContractMember2024-04-012024-06-300000051253us-gaap:ForeignExchangeContractMember2023-04-012023-06-300000051253us-gaap:CommodityContractMember2024-04-012024-06-300000051253us-gaap:CommodityContractMember2023-04-012023-06-300000051253us-gaap:ForeignExchangeContractMember2024-01-012024-06-300000051253us-gaap:ForeignExchangeContractMember2023-01-012023-06-300000051253us-gaap:CommodityContractMember2024-01-012024-06-300000051253us-gaap:CommodityContractMember2023-01-012023-06-300000051253us-gaap:CashFlowHedgingMemberiff:CrossCurrencySwapsMember2024-04-012024-06-300000051253us-gaap:CashFlowHedgingMemberiff:CrossCurrencySwapsMember2023-04-012023-06-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-04-012024-06-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2024-04-012024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2024-04-012024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2023-04-012023-06-300000051253us-gaap:CashFlowHedgingMemberiff:ForeignCurrencyContractsMember2024-01-012024-06-300000051253us-gaap:CashFlowHedgingMemberiff:ForeignCurrencyContractsMember2023-01-012023-06-300000051253us-gaap:CashFlowHedgingMemberiff:CrossCurrencySwapsMember2024-01-012024-06-300000051253us-gaap:CashFlowHedgingMemberiff:CrossCurrencySwapsMember2023-01-012023-06-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-06-300000051253iff:CrossCurrencySwapsMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentyFourMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2024-01-012024-06-300000051253iff:SeniorNotesEuroNotesDueTwoThousandTwentySixMemberus-gaap:NetInvestmentHedgingMember2023-01-012023-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-03-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-04-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-04-012024-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-12-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2024-01-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-03-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-04-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-04-012023-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000051253us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-12-310000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000051253us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300000051253us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-04-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-04-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-04-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-04-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2024-01-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-01-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-01-012023-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300000051253us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300000051253iff:BankGuaranteesCommercialGuaranteesStandbyLettersOfCreditAndSuretyBondsMember2024-06-300000051253iff:PledgedAssetsMember2024-06-300000051253us-gaap:RevolvingCreditFacilityMemberiff:CitibankN.AMember2024-06-300000051253srt:ChiefExecutiveOfficerMember2019-10-292019-10-290000051253srt:ChiefExecutiveOfficerMember2020-03-112020-03-110000051253us-gaap:UnfavorableRegulatoryActionMember2024-01-012024-06-300000051253iff:WastewaterDisposalMemberiff:SolaeLLCMemphisMember2024-06-30

For the transition period from                      to                         

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No   ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑   No   ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ☐ No  ☑ 

Number of shares of common stock outstanding as of July 31, 2024: 255,659,175

_______________________

(1)Cash dividends declared per common share were $0.40 and $0.81 for the three months ended June 30, 2024 and June 30, 2023, respectively, and $0.80 and $1.62 per share for the six months ended June 30, 2024 and June 30, 2023, respectively.

International Flavors & Fragrances Inc. and its subsidiaries (the “Registrant,” “IFF,” “the Company,” “we,” “us” and “our”) is a leading creator and manufacturer of food, beverage, health & biosciences, scent and pharma solutions and complementary adjacent products, including natural health ingredients, which are used in a wide variety of consumer products. Our products are sold principally to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, sweeteners, dietary supplements, food protection, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products.

The accompanying interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes included in our 2023 Annual Report on Form 10-K (“2023 Form 10-K”), filed on February 28, 2024 with the Securities and Exchange Commission (“SEC”).

The interim Consolidated Financial Statements are prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States of America for interim financial information and with the rules and regulations for reporting on Form 10-Q, and are unaudited. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP in the United States of America have been condensed or omitted, if not materially different from the 2023 Form 10-K. The year-end balance sheet data included in this Form 10-Q was derived from the audited financial statements. In the opinion of management, all adjustments, which consist of normal recurring adjustments necessary for a fair statement of the interim Consolidated Financial Statements, have been made.

The Company revised Interest expense from $116 million to $101 million, and Other income, net from $26 million to $11 million, on its Consolidated Statements of Income and Comprehensive Income (Loss) for the three months ended June 30, 2023. The Company also revised Interest expense from $227 million to $201 million and Other income, net from $34 million to $8 million for the six months ended June 30, 2023. These adjustments had no impact on net income and reflect certain adjustments made to interest expense associated with the Company’s cash pooling arrangements. The impacts of these corrections are also presented in the related footnotes.

The preparation of financial statements requires management to make estimates and judgments that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. The inputs into the Company’s judgments and estimates take into account the ongoing global current events and adverse macroeconomic impacts on our critical and significant accounting estimates, including estimates associated with future cash flows that are used in assessing the risk of impairment of certain assets. Actual results could differ from those estimates.

Cash, cash equivalents and restricted cash reported in the Company’s balance sheet as of June 30, 2024, December 31, 2023, June 30, 2023 and December 31, 2022 were as follows:

The Company has various factoring agreements globally under which it can factor up to approximately $300 million of its trade receivables (“Company’s own factoring agreements”). In addition, the Company utilizes factoring agreements sponsored by certain customers. Under all of the arrangements, the Company sells the trade receivables on a non-recourse basis to unrelated financial institutions and accounts for the transactions as sales of receivables. The applicable receivables are removed from the Company’s Consolidated Balance Sheets when the cash proceeds are received by the Company.

The Company sold a total of approximately $882 million and $858 million of receivables under the Company’s own factoring agreements and customer sponsored factoring agreements for the six months ended June 30, 2024 and 2023, respectively. The cost of participating in these programs was approximately $8 million and $7 million for the three months ended June 30, 2024 and 2023, respectively, and was approximately $14 million and $12 million for the six months ended June 30, 2024 and 2023, respectively. These costs are included as a component of interest expense. Under the Company’s own factoring agreements for which the Company has continued responsibility to collect receivables and provide to its sponsor, it sold approximately $436 million and $425 million of receivables for the six months ended June 30, 2024 and 2023, respectively. The outstanding principal amounts of receivables under the Company’s own factoring agreements amounted to approximately $210 million and $196 million as of June 30, 2024 and December 31, 2023, respectively. The proceeds from the sales of receivables are included in Net cash provided by operating activities in the Consolidated Statements of Cash Flows.

As of June 30, 2024, the Company reported $1.775 billion of trade receivables, net of allowances of $27 million. Based on the aging analysis as of June 30, 2024, less than 1% of the Company’s accounts receivable were past due by over 365 days based on the payment terms of the invoice.

The following is a roll-forward of the Company’s allowances for bad debts for the six months ended June 30, 2024 and 2023.

Inventories are stated at the lower of cost (on a weighted-average basis) or net realizable value. The Company’s inventories consisted of the following:

In the fourth quarter of 2023, the Company entered into a supply chain financing (“SCF”) program. The SCF program is expected to be available to U.S. based suppliers starting in the second half of 2024. The Company makes continuous efforts to improve working capital efficiency and has worked with suppliers to optimize payment terms and conditions. The Company’s current payment terms with a majority of suppliers generally range from 0 to 180 days, which is deemed to be commercially reasonable. The Company’s SCF program is voluntary and will allow its suppliers to elect to sell the receivables owed to them by the Company to a third-party financial institution. The suppliers, at their own discretion, will determine the invoices they want to sell and directly negotiate the arrangements with the participating third-party financial institution. Supplier participation in the program is solely the decision of the supplier and has no bearing on the Company’s payment terms and amounts due with the supplier. The Company’s responsibility will be limited to making payments based upon the agreed contractual terms and arrangements. The Company will not provide any form of guarantees under the SCF program and will have no economic interest in the suppliers’ decision to participate in the SCF program. Amounts due to suppliers that elect to participate in the SCF program will be included in Accounts payable on the Consolidated Balance Sheets. The Company, or the third-party financial institution, may choose to terminate the agreement of the SCF program at any time upon 30 days’ prior written notice.

The third-party financial institution may also terminate the agreement of the SCF program at any time upon three business days’ prior written notice in the event there are insufficient funds available for disbursements. As of June 30, 2024 and December 31, 2023, there were no amounts outstanding related to suppliers’ participation in the SCF program.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The ASU was issued to further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This guidance is effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact that this guidance will have on its income tax disclosures.

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The ASU intends to improve reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses that are regularly provided to the Chief Operating Decision Maker and included within segment profit and loss. This guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its reportable segment disclosures.

A reconciliation of the shares used in the computation of basic and diluted net income per share is as follows:

			Three Months Ended June 30,												Six Months Ended June 30,
(AMOUNTS IN MILLIONS EXCEPT PER SHARE AMOUNTS)			2024						2023						2024						2023
Net Income
Net income attributable to IFF shareholders			$	170					$	27					$	230					$	18
Adjustment related to (increase) in redemption value of redeemable non-controlling interests in excess of earnings allocated			—						(1)						—						(1)
Net income available to IFF shareholders			$	170					$	26					$	230					$	17
Shares
Weighted average common shares outstanding (basic)			255						255						255						255
Adjustment for assumed dilution:
Stock options and restricted stock awards			1						—						1						—
Weighted average shares assuming dilution (diluted)			256						255						256						255
Net Income per Share
Net income per share - basic(1)			$	0.67					$	0.11					$	0.90					$	0.07
Net income per share - diluted(1)			0.66						0.11						0.90						0.07

_______________________

(1)For the three months ended June 30, 2023, the basic and diluted net income per share cannot be recalculated based on the information presented in the table above due to rounding.

The Company declared a quarterly dividend to its shareholders of $0.40 and $0.81 per share for the three months ended June 30, 2024 and 2023, respectively. For the six months ended June 30, 2024 and 2023, the Company declared quarterly dividends to its shareholders totaling $0.80 and $1.62, respectively.

For the three and six months ended June 30, 2024, there were approximately 0.3 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net income per share in the period. For the three and six months ended June 30, 2023, there were approximately 0.4 million share equivalents that had an anti-dilutive effect and therefore were excluded from the computation of diluted net loss per share.

The Company has issued shares of Purchased Restricted Stock Units (“PRSUs”) which contain rights to non-forfeitable dividends while these shares are outstanding and thus are considered participating securities. Such securities are required to be included in the computation of basic and diluted earnings per share pursuant to the two-class method.

The Company did not present the two-class method since the difference between basic net income per share for both unrestricted common shareholders and PRSU shareholders for the three and six months ended June 30, 2024 was less than $0.01 per share. The difference between basic net income per share for both unrestricted common shareholders and PRSU shareholders for the three months ended June 30, 2023 was less than $0.01 per share. There was no difference between basic net income per share for both unrestricted common shareholders and PRSU shareholders for the six months ended June 30, 2023. The difference between diluted net income per share for both unrestricted common shareholders and PRSU shareholders for the three and six months ended June 30, 2024 and 2023 was less than $0.01 per share. In addition, the number of PRSUs outstanding as of June 30, 2024 and 2023 was not material. Net income allocated to such PRSUs was not material for the three and six months ended June 30, 2024 and 2023.

During the third quarter of 2023, the Company announced it had entered into an agreement to sell its Cosmetic Ingredients business, which was a part of the Scent segment. The Company completed the divestiture on April 2, 2024, and received cash proceeds of approximately $841 million. The sale consideration is subject to certain post-closing adjustments, which is primarily related to cash, indebtedness and working capital balances.

The following table summarizes the fair value of sale consideration received in connection with the business divestiture:

The net proceeds received from the business divestiture presented under Cash flows from investing activities represent the cash portion of the sale consideration, which was determined as the fair value of sale consideration adjusted by the cash transferred to the buyer as part of the transaction. Amounts paid for direct costs to sell are presented under Cash flows from operating activities. The following table summarizes the different components of net proceeds received from business divestiture presented under Cash flows from investing activities:

The carrying amount of net assets associated with the business unit, adjusted for currency translation adjustment, was approximately $466 million. The major classes of assets and liabilities sold consisted of the following:

As a result of the business divestiture, the Company recognized a pre-tax gain of approximately $365 million, subject to certain post-closing adjustments, presented in (Gains) losses on business disposals on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and six months ended June 30, 2024. The total income tax expense/(benefit) recognized was approximately $34 million, with approximately $(7) million that was recognized during the year ended December 31, 2023.

The Company completed the divestiture of a Portion of the Savory Solutions business on May 31, 2023, and received net cash proceeds of approximately $821 million. In addition, a receivable of approximately $37 million was recorded which reflected the remaining sale consideration that was received in January 2024.

As a result of the divestiture, the Company recognized a pre-tax loss of approximately $10 million presented in (Gains) losses on business disposals on the Consolidated Statements of Income and Comprehensive Income (Loss) for the three and six months ended June 30, 2023. There was a true-up settlement of $7 million for the three months ended December 31, 2023, resulting in a cumulative pre-tax loss of approximately $3 million. The Company also recognized the income tax effects associated with the transaction of approximately $7 million based on estimates as of June 30, 2023.

As part of the liquidation of a business in Russia for the sale of the portion of the Savory Solutions business, the Company recognized a pre-tax loss of approximately $10 million presented in the (Gains) losses on business disposals, and tax benefits of approximately $2 million presented in Provision for income taxes on the Consolidated Statements of Income and Comprehensive Income (Loss) for the six months ended June 30, 2023.

During the first quarter of 2024, the Company announced it had entered into an agreement to sell its Pharma Solutions business, that is primarily made up of most businesses within the Company's existing Pharma Solutions reportable operating segment as well as certain adjacent businesses (the "Pharma Solutions disposal group"). The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2025.

The sale does not constitute a strategic shift of the Company’s operations and does not, and will not, have major effects on the Company’s operations and financial results. Therefore, the transaction does not meet the discontinued operations criteria.

The Company determined that the assets and liabilities of the Pharma Solutions disposal group met the criteria to be presented as “held for sale” during the second quarter of 2024. As a result, as of June 30, 2024, such assets and liabilities were classified as held for sale on the Consolidated Balance Sheets. The carrying value is subject to change based on developments leading up to the closing date.

The classification of the Pharma Solutions disposal group as held for sale was considered an event or change in circumstance which required an assessment of the existing Pharma Solutions reporting unit. The Company performed a pre-classification goodwill impairment test and determined that the fair value of the Pharma Solutions reporting unit exceeded the carrying value.

The Company engaged an independent third party to determine the fair value of the assets held for sale as of May 1, 2024, based upon the sale price including earn outs expected to be received from the buyer. The fair value of the earn out was based on a Monte Carlo simulation. Goodwill was allocated to the Pharma Solutions disposal group based upon the relative fair value of the businesses included in the disposal group compared to the reporting units to which the businesses relate. The Company then performed a post-classification goodwill impairment test and determined that the fair value was less than the carrying value of the Pharma Solutions disposal group. As such, the Company recorded a non-cash goodwill impairment charge of $64 million.

The Company also performed a goodwill impairment test of the remaining businesses in the Pharma Solutions reporting unit that were not classified as held for sale and determined that the fair value exceeded the carrying value.

The Company engaged an independent third-party to determine an updated fair value of the Pharma Solutions disposal group as of June 30, 2024. The Company determined that the fair value of $2,686 million (fair value of $2,717 million less estimated costs to sell of $31 million) of the Pharma Solutions disposal group was less than the carrying value. As such, the Company recorded a loss of $282 million in the second quarter of 2024 to adjust the carrying value of the disposal group to its fair value less cost to sell. The Company recorded the loss on classification of held for sale as a valuation allowance on the group of assets held for sale, without allocation to the individual assets or major classes of assets within the group. Due to the nature of estimates, the carrying value is subject to change based on developments leading up to the closing date, and the actual amounts realized upon sale may differ from amounts recognized as of June 30, 2024. Any difference will be recognized as a gain or loss in future financial statements.

The Company recognized income tax benefits of $56 million related to loss on assets classified as held for sale for the Pharma Solutions disposal group.

In addition, pursuant to the terms agreed under the 2026 Term Loan Facility, a portion of the net cash proceeds received from the sale of the Pharma Solutions disposal group, when and if completed, must be used to repay our borrowings under the 2026 Term Loan Facility. Therefore, the Company reclassified the 2026 Term Loan Facility balance from "Long-term debt" to "Short-term debt and current portion of long-term debt" (see Note 13).

As of December 31, 2023, the assets and liabilities of the Cosmetic Ingredients business met the criteria to be presented as "held for sale". The Company completed the divestiture on April 2, 2024 and therefore the assets and liabilities of the Cosmetic Ingredients business are not included in the Company's Consolidated Balance Sheets as of June 30, 2024.

Included in the Company’s Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 are the following carrying amounts of the assets and liabilities held for sale:

(DOLLARS IN MILLIONS)			June 30, 2024			December 31, 2023
Assets
Cash and cash equivalents			$	3		$	26
Trade receivables, net			170			15
Inventories			260			18
Property, plant and equipment, net			358			7
Goodwill(1)			1,163			276
Other intangible assets, net			1,056			146
Operating lease right-of-use assets			13			9
Other assets			74			9
Less: Loss recognized on assets held-for-sale(2)			(282)			—
Total assets held-for-sale			$	2,815		$	506
Liabilities
Accounts payable			$	74		$	4
Deferred tax liability			61			24
Other liabilities			96			18
Total liabilities held-for-sale			$	231		$	46

_______________________

(1)The goodwill balance in assets held for sale for the Pharma Solutions disposal group as of June 30, 2024, is presented net of $64 million of goodwill impairment.

(2)Includes the impact of $102 million, primarily related to loss on foreign currency translation, expected to be reclassified out of accumulated other comprehensive loss upon close of the sale.

Restructuring and other charges primarily consist of separation costs for employees including severance, outplacement and other employee benefit costs (“Severance”), charges related to the write-down of fixed assets of plants to be closed (“Fixed asset write-down”) and all other related restructuring (“Other”) costs. All restructuring and other charges are separately stated on the Consolidated Statements of Income and Comprehensive Income (Loss).

For the six months ended June 30, 2024, the Company had approximately $2 million of charges related to a lease impairment. Since the inception of the restructuring activities, there have been a total of approximately 215 headcount reductions and the Company has expensed approximately $49 million. As of December 31, 2023, the restructuring activities were completed related to employee exits. The Company continues to evaluate its owned and leased properties following the combination of IFF and DuPont de Nemours, Inc’s nutrition and biosciences business (“Merger with N&B”) and may incur additional costs to further consolidate its footprint.

In December 2022, the Company announced a restructuring program mainly related to headcount reduction to improve its organizational and operating structure, drive efficiencies and achieve cost savings. For the six months ended June 30, 2024, the Company incurred approximately $3 million of charges related to severance. Since the inception of the restructuring program, the Company has expensed approximately $73 million and there have been a total of approximately 670 actual and planned headcount reductions.

Changes in restructuring liabilities during the six months ended June 30, 2024 were as follows: